Latest Anticoagulants Stories
BIDMC researcher says improvement in survival rates best 'since introduction of aspirin' An oral anti-clotting drug, when added to standard medical treatment for acute coronary syndrome, lowered the risk of death, heart attack or stroke an average of 16 percent, according to research presented at the American Heart Association's Scientific Sessions. The results were also published online by the New England Journal of Medicine. The drug, rivaroxaban, proved effective in preventing the...
ORLANDO, Fla., Nov. 14, 2011 /PRNewswire/ -- Patients using Pradaxa (dabigatran), a new blood thinner aimed at preventing stroke and blood clots, failed to remain on the treatment 17 percent of the time after the first four months, according to a study presented at the American Heart Association's Scientific Sessions. (Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO) The research conducted by Medco Research Institute(TM), a subsidiary of Medco Health Solutions, Inc. (NYSE: MHS),...
RIDGEFIELD, Conn., Nov. 14, 2011 /PRNewswire/ -- A new retrospective subanalysis of the RE-LY® trial found Pradaxa® (dabigatran etexilate mesylate) capsules 150mg twice daily reduced the risk of stroke and systemic embolism compared to warfarin in patients with non-valvular atrial fibrillation (NVAF) irrespective of the presence of symptomatic heart failure (sHF), with no significant interaction for major bleeding events.(1) The results were presented today at the American Heart...
ORLANDO, Fla., Nov. 13, 2011 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that adding oral rivaroxaban to standard antiplatelet therapy significantly reduced the composite primary efficacy endpoint of cardiovascular-related deaths, heart attacks or strokes in patients with acute coronary syndrome (ACS) compared to those receiving standard therapy alone. Results from the pivotal Phase 3 ATLAS ACS 2 TIMI 51 trial presented today at...
SILVER SPRING, Md., Nov. 4, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved the anti-clotting drug Xarelto (rivaroxaban) to reduce the risk of stroke in people who have abnormal heart rhythm (non-valvular atrial fibrillation). (Logo: <font size="2" face="Arial">http://photos.prnewswire.com/prnh/20090824/FDALOGO</font>) Atrial fibrillation occurs in more than 2 million Americans and is one of the most common types of abnormal...
RARITAN, N.J., Nov. 4, 2011 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved XARELTO® to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. XARELTO® is the only oral anticoagulant approved in the U.S. that offers once-daily dosing, without the need for routine blood monitoring. To view the multimedia assets associated with this release, please click:...
New research has the potential to revolutionize the treatment of atrial fibrillation (AF), a condition affecting a quarter of a million Canadians which is expected to strike even more in the coming years, as the Canadian population ages. AF is the most common type of heart arrhythmia and puts those affected at a three to five times greater risk for stroke. Now, there is a new drug poised to battle the condition. "The majority of patients with atrial fibrillation need an anticoagulant....
(Ivanhoe Newswire) – Atrial fibrillation (AF) is the most common type of heart arrhythmia that causes five times greater risk for stroke. A new drug has the potential to revolutionize the treatment of AF and battle the deadly disorder. "The majority of patients with atrial fibrillation need an anticoagulant. The current anticoagulant can be a burden for physicians and patients due to its side effects and narrow therapeutic range," Dr. Justin Ezekowitz, from the University of Alberta, was...
BEDMINSTER, N.J., Oct. 25, 2011 /PRNewswire/ -- Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that Timothy J. Maines has joined the Company as Vice President of Quality. In this newly created position, reporting directly to Chief Operating Officer, Drs. Ben Machielse, Mr. Maines will be responsible for Quality, Validation and CMC development at Omthera. Mr. Maines brings to the Company more than 25 years of pharmaceutical,...
INDIANAPOLIS, Oct. 25, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announces withdrawal of its Xigris® [drotrecogin alfa (activated)] product in all markets following results of the PROWESS-SHOCK study, which showed the study did not meet the primary endpoint of a statistically significant reduction in 28-day all-cause mortality in patients with septic shock. The company is working with regulatory agencies on this withdrawal, and is in the process of notifying health care...
